On June 15, 2023, Acotec Scientific Holdings Limited entered into a memorandum of understanding (the "MOU") with Boston Scientific Group plc ("BSG"), pursuant to which Boston Scientific Corporation ("BSC", together with its subsidiaries but excluding the Group, the "BSC Group") and Group confirmed their mutual understanding that they intend to explore the opportunities to collaborate in several areas, including, among other things, research and development, manufacturing, and sales and marketing (collectively, the "Collaborations"). The Company and the BSC Group intend to explore the following areas of Collaborations by leveraging each party's advantages on technology, technique, experience and resources, including: enhancing research and development on cardiovascular diseases and developing products for markets including United States, China, Japan and European countries; developing products for the treatment of CTO (chronic total occlusion) lesions, lower extremity artery stenosis, varicose veins, access maintenance for dialysis patients and other areas; manufacturing certain products on an OEM (original equipment manufacturer) basis for the other party to achieve cost efficiency; cross selling or co-branding certain products in areas such as periphery, coronary artery, tumor, urinary, and andrology to maximize channel utilization and product value; and supporting the registration of the other party's products. The terms and conditions of the Collaborations are subject to further negotiations between the parties thereof, which has not been finalized as at the date of this announcement.

As agreed by the Company and BSG, the MOU does not constitute a legally binding agreement on the parties to the MOU. Nothing in the MOU imposes an obligation on either parties thereof to continue discussions or negotiations in connection with the Collaborations and either party thereof may, at its sole discretion, terminate discussions and negotiations with, the other party thereof at any time.